Radar›Companies›Pharmaceutical Preparations Stocks in USA: Revenue Cohort 20
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Revenue Cohort 20

A five-company pharmaceutical preparations cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderVerastem · 52
Strongest available pathJanux Therapeutics · -44.9%
Widest latest marginEmmaus Medical · -60.2%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1VSTM · Nasdaq

Verastem

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Needham, Massachusetts$653.9M market cap
View full Companies Radar profile
52Moderate
Snapshot price$7.22as of page date
Monthly-close return-76.8%five-year window
FY2024 revenue$0.01BVerastem, Inc.
Net margin-1306.4%FY2024
P/E snapshot-9.6xone ratio, not a verdict
Prism attention38.2%share across these five
Filing track recordRevenue, USD billions
-42.7%
$0$0.0B$0.1B$0.1BFY2019: $0.017BFY2020: $0.089BFY2021: $0.002BFY2022: $0.003BFY2024: $0.010B20192020202120222024
FY2019–FY2024 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -13.0%
52-week position48% through range
$3.43$11.25
News mentions1.0K
Community mentions46partial coverage
U.S.-scope patents214
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal69/100
Management stability90/100
Market position3/100
Capital-event signal72/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2PRLD · Nasdaq

Prelude Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2016Philadelphia, Pennsylvania$435.7M market cap
View full Companies Radar profile
42Cautious
Snapshot price$5.47as of page date
Monthly-close return-82.2%five-year window
FY2025 revenue$0.01BPrelude Therapeutics Inc
Net margin-819.6%FY2025
P/E snapshot-7.3xone ratio, not a verdict
Prism attention13.5%share across these five
Filing track recordRevenue, USD billions
+73.4%
$0$0.0B$0.0B$0.0BFY2024: $0.007BFY2025: $0.012B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 73.4%
52-week position77% through range
$0.98$6.83
News mentions365
Community mentions4partial coverage
U.S.-scope patents311
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal44/100
Management stability90/100
Market position7/100
Capital-event signal50/100
Innovation pulse9/100
Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3JANX · Nasdaq

Janux Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2017San Diego, California$1.10B market cap
View full Companies Radar profile
41Cautious
Snapshot price$18.03as of page date
Monthly-close return-44.9%five-year window
FY2025 revenue$0.01BJanux Therapeutics, Inc.
Net margin-1136.2%FY2025
P/E snapshot-6.9xone ratio, not a verdict
Prism attention16.5%share across these five
Filing track recordRevenue, USD billions
+175.0%
$0$0.0B$0.0B$0.0BFY2021: $0.004BFY2022: $0.009BFY2023: $0.008BFY2024: $0.011BFY2025: $0.010B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 28.8%
52-week position25% through range
$12.12$35.34
News mentions448
Community mentions6partial coverage
U.S.-scope patents170
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal38/100
Management stability90/100
Market position0/100
Capital-event signal71/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4SDEV · NYSE

NovaBay Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2000Emeryville$47.3M market cap
View full Companies Radar profile
40Cautious
Snapshot price$0.93as of page date
Monthly-close return-100.0%five-year window
FY2024 revenue$0.01BStablecoin Development Corp
Net margin-73.8%FY2024
Prism attention24.5%share across these five
Filing track recordRevenue, USD billions
-1.5%
$0$0.0B$0.0B$0.0BFY2020: $0.010BFY2021: $0.008BFY2022: $0.014BFY2023: $0.015BFY2024: $0.010B20202021202220232024
FY2020–FY2024 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -0.4%
52-week position0% through range
$0.93$99.75
News mentions665
Community mentions0partial coverage
U.S.-scope patents116
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal39/100
Management stability90/100
Market position17/100
Capital-event signal56/100
Innovation pulse3/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 5 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 4 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5EMMA · OTC

Emmaus Medical

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2000Torrance, California$5.8M market cap
View full Companies Radar profile
33Cautious
Snapshot price$0.08as of page date
Monthly-close return-94.6%five-year window
FY2025 revenue$0.01BEmmaus Life Sciences, Inc.
Net margin-60.2%FY2025
Prism attention7.3%share across these five
Filing track recordRevenue, USD billions
-39.6%
$0$0.0B$0.0B$0.0BFY2021: $0.021BFY2022: $0.018BFY2023: $0.030BFY2024: $0.017BFY2025: $0.012B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -11.8%
52-week position100% through range
$0.01$0.08
News mentions197
Community mentions0partial coverage
U.S.-scope patents49
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal26/100
Management stability90/100
Market position10/100
Capital-event signal48/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 1 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Janux Therapeutics
-44.9%
Verastem
-76.8%
Prelude Therapeutics
-82.2%
Emmaus Medical
-94.6%
NovaBay Pharmaceuticals
-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Prelude Therapeutics
$0.01B
Emmaus Medical
$0.01B
Verastem
$0.01B
Janux Therapeutics
$0.01B
NovaBay Pharmaceuticals
$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Emmaus Medical
-60.2%
NovaBay Pharmaceuticals
-73.8%
Prelude Therapeutics
-819.6%
Janux Therapeutics
-1136.2%
Verastem
-1306.4%

Prism news attention

Normalized share across these five names; attention is not quality.

Verastem
38.2%
NovaBay Pharmaceuticals
24.5%
Janux Therapeutics
16.5%
Prelude Therapeutics
13.5%
Emmaus Medical
7.3%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Verastem leads the conversation

It holds 38.2% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.01B.

Price path

Janux Therapeutics leads the available price paths

Its monthly-close return is -44.9% for the five-year window. At the other end, NovaBay Pharmaceuticals is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Emmaus Medical has the widest latest margin

Its FY2025 net margin is -60.2%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Verastem shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -9.6x while its five-year window price return is -76.8%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · VSTM

Verastem

1,034available Prism news records

Prism top themes

Price action & investor response
65
Earnings & financial performance
25
Legal, arbitration & regulatory
21
Capital allocation & transactions
15
Macro demand & rates
15

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-33.2%131 latest 12m vs 196 prior 12m
2024-01: 4 mentions2024-02: 2 mentions2024-03: 16 mentions2024-04: 9 mentions2024-05: 15 mentions2024-06: 12 mentions2024-07: 13 mentions2024-08: 2 mentions2024-09: 2 mentions2024-10: 13 mentions2024-11: 3 mentions2024-12: 9 mentions2025-01: 17 mentions2025-02: 62 mentions2025-03: 23 mentions2025-04: 12 mentions2025-05: 20 mentions2025-06: 20 mentions2025-07: 7 mentions2025-08: 6 mentions2025-09: 12 mentions2025-10: 15 mentions2025-11: 5 mentions2025-12: 9 mentions2026-01: 8 mentions2026-02: 22 mentions2026-03: 14 mentions2026-04: 15 mentions2026-05: 17 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

95.9% positive+0.2 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

angiogenesis inhibitors 25stock price 22stock performance 18share price 13ascites ovarian cancer 12cancer biomarkers 10bloating ovarian cancer 7gene therapy rare diseases 6

Keyword tag occurrences in available Prism news records.

Coverage: 2010-11-16–2026-06-01 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

VSTM

Verastem

46 mentions
Stock and valuation
28
Products, pricing and logistics
2
Workplace and hiring
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 46 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

VSTM

Verastem

through 2026-01-31
Company announcements 7Leadership changes 5Earnings releases 4
  1. Earnings releases

    Based on Verastem’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $11.24 million and a GAAP net loss of $98.52 million.

  2. Leadership changes

    John Johnson, a board member since 2020, has been appointed as chairman of the board of directors succeeding Dr. Kauffman.

  3. Company announcements

    Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 138,000 shares of its common stock to nine new employees.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PRLD

Prelude Therapeutics

through 2025-11-12
Company announcements 5Leadership changes 5Earnings releases 4Business contracts 1
  1. Earnings releases

    (UNAUDITED) Three Months Ended September 30, (in thousands, except share and per share data) 2025 2024 Revenue $ 6,500 $ 3,000 Operating expenses Research and development 21,708 29,457 General and administrative 5,210 7,919 Total operating expenses 26,918 37,376 Loss from operations (20,418 ) (34,376 ) Other income, net 693 2,105 Net loss $ (19,725 ) $ (32,271 ) Per share information: Net loss per share of common stock, basic and diluted $ (0.26 ) $ (0.43 )

  2. Company announcements

    Company to release third quarter 2025 financial results and conduct an investor conference call on November 12, 2025

  3. Business contracts

    Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program, including Prelude’s library of preclinical candidates.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

JANX

Janux Therapeutics

through 2026-02-05
Leadership changes 2Listing / IPO 2
  1. Leadership changes

    Janux Therapeutics announced chief medical officer Zachariah McIver, DO, PhD is leaving the company to pursue other opportunities.

  2. Listing / IPO

    Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it has commenced an underwritten public offering of $300.0 million of shares of its common stock or, in lieu of common stock issued to certain investors that so choose, pre-funded warrants to purchase shares of its common stock.

  3. Leadership changes

    Janux Therapeutics named William Go, MD, PhD as chief medical officer, effective January 26.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SDEV

NovaBay Pharmaceuticals

through 2025-10-21
Earnings releases 15Asset acquisitions 5Company announcements 5M&A 4Regulatory 4
  1. Company announcements

    NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American’s continued listing standards.

  2. Regulatory

    The NYSE American formally notified NovaBay in a letter dated October 20, 2025, confirming that the Company had successfully addressed and resolved all deficiencies related to Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide.

  3. M&A

    NovaBay Pharmaceuticals (NBY) stock rocketed higher on Wednesday after the biopharmaceutical company announced a $6 million securities purchase agreement with private investor David Lazar.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EMMA

Emmaus Medical

through 2025-12-31
Earnings releases 7Company announcements 1Regulatory 1
  1. Regulatory

    Endari® is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman.

  2. Earnings releases

    Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2024.

  3. Company announcements

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 96–103. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with Emmaus Medical and Emmaus Medical

Emmaus Medical has the largest displayed latest revenue at $0.01B; Emmaus Medical has the widest displayed latest margin at -60.2%.

Open Emmaus Medical in Companies Radar
Comparisons
Anomalies

NovaBay Pharmaceuticals has the widest attention-readiness rank gap

It ranks #2 by measured news attention (24.5%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open NovaBay Pharmaceuticals in Companies Radar

Janux Therapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +175.0% while its available monthly-close return is -44.9%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Janux Therapeutics in Companies Radar
Explanations

Attention measures coverage volume, not quality

Verastem's 38.2% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Verastem in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Verastem's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 52/100 score.

Open Verastem in Companies Radar

Stress-test the largest divergence before forming a view

Compare Janux Therapeutics's profile with Janux Therapeutics's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Janux Therapeutics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon